Gentronix Secures R&D Award
News Apr 11, 2006
The purpose of the two-year grant is to assist small businesses initiate or develop new research programmes, and will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Greenscreen GC, the company’s commercially available yeast-based assay, is already proving an early screening tool in the drug development process.
In particular the assay’s high specificity is demonstrated by the extremely low incidence of false positives compared to other available tests.
The SBRI grant will enable Gentronix to build on this early success, and research and develop additional assays using alternative cell lines.
The aim is to increase screening sensitivity so that no genetically toxic compounds are missed whilst retaining the high specificity required, ensuring potentially valuable lead compounds are not eliminated from further development.
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE